Hamilton Locke is pleased to have advised EMVision Medical Devices Limited (ASX: EMV) on its $15.28 million strategic placement with Keysight Technologies Inc (NYSE: KEYS).
The deal represents a significant milestone for EMVision, positioning the company for accelerated growth, market penetration, and continued innovation in medical imaging technology. The investment will facilitate and fund EMVision’s entry into the market with its emu™ device, a portable brain-scanning technology aimed at improving stroke and neurological disorder diagnosis and treatment outcomes.
Commenting on the transaction, Hamilton Locke Partner Jeremy Newman said, “This collaboration between EMVision and Keysight Technologies marks a pivotal moment in EMVision’s growth trajectory and highlights the strength of its innovative medical technologies. We are delighted to have collaborated closely with the team at EMVision throughout the deal process and are proud to have assisted them in achieving this milestone.”
The team at Hamilton Locke was led by Partner Jeremy Newman and included Partner Sarah Gilkes, Senior Associate Janice Yew and Lawyer Brendon Banks.
Click here to read EMVision’s full announcement.
